

WHAT IS CLAIMED IS:

1. ~~An antihistaminic syrup formulation containing about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid, including salts thereof.~~

2. The syrup of claim 1, which contains an antihistaminic ingredient selected from the group consisting of: loratadine; descarboethoxyloratadine; azatadine; and any combination of two or more thereof.

3. The syrup of claim 1, which contains the antihistaminic ingredient loratadine.

4. The syrup of claim 1, which contains the antihistaminic ingredient descarboethoxyloratadine.

5. The syrup of claim 1, which contains the antihistaminic ingredient azatadine.

6. The syrup of claim 1, wherein the aminopolycarboxylic acid is selected from the group consisting of: iminodiacetic acid; methyliminodiacetic acid; nitrilotriacetic acid; ethylenediaminetetraacetic acid; diethylenetriaminepentaacetic acid; 1,2-diaminocyclohexane-tetraacetic acid; N-hydroxyethylenediaminetriacetic acid; and any combination of two or more thereof.

7. The syrup of claim 1, wherein the aminopolycarboxylic acid comprises ethylenediaminetetraacetic acid.

8. The syrup of claim 1, in which the aminopolycarboxylic acid comprises about 0.1 to 1 mg/mL.

Amn.
a²

a

09899764.070501

9. The syrup of claim 1, in which the aminopolycarboxylic acid comprises about 0.25 to about 0.5 mg/mL.

10. The syrup of claim 1, further containing a therapeutically effective amount of a decongestant, an analgesic, an antitussive, an expectorant, or any combination of two or more thereof.

11. The syrup of claim 1, further containing a decongestant selected from the group consisting of pseudoephedrine and phenylpropanolamine.

12. The syrup of claim 1, further containing the decongestant pseudoephedrine.

13. The syrup of claim 12, which contains the antihistaminic ingredient loratadine.

14. An antihistaminic syrup formulation containing loratadine or descarboethoxyloratadine and about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid or a salt thereof.

15. The syrup of claim 14, wherein the aminopolycarboxylic acid is selected from the group consisting of: iminodiacetic acid; methyliminodiacetic acid; nitrilotriacetic acid; ethylenediaminetetraacetic acid; diethylenetriaminepentaacetic acid; 1,2-diaminocyclohexane-tetraacetic acid; N-hydroxyethylenediaminetriacetic acid; and any combination of two or more thereof.

16. The syrup of claim 14, wherein the aminopolycarboxylic acid comprises ethylenediaminetetraacetic acid.

17. The syrup of claim 14, in which the aminopolycarboxylic acid comprises about 0.1 to 1 mg/mL.

0989764-070501

17. The syrup of claim 14, in which the aminopolycarboxylic acid comprises about 0.25 to about 0.5 mg/mL.

18. The syrup of claim 14, further containing an analgesic.

5

19. The syrup of claim 14, further containing a decongestant selected from the group consisting of pseudoephedrine and phenylpropanolamine.

10

20. The syrup of claim 19, further containing an analgesic.

21. An antihistaminic syrup formulation containing loratadine and about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid or a salt thereof.

15

22. An antihistaminic syrup formulation containing descarboethoxyloratadine and about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid or a salt thereof.

0989764.070501
T05070"49768660

Add
a³